{"id":991400,"date":"2026-08-06T13:33:44","date_gmt":"2026-08-06T17:33:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/"},"modified":"2026-08-06T13:33:44","modified_gmt":"2026-08-06T17:33:44","slug":"silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/","title":{"rendered":"Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <b><br \/>\n          <i>Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption<\/i><br \/>\n        <\/b>\n      <\/p>\n<p>SARASOTA, FLA., Aug.  06, 2026  (GLOBE NEWSWIRE) &#8212;  Silo Pharma (Nasdaq: SILO) (\u201cSilo\u201d or \u201cthe Company\u201d), a managed AI agent platform and developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that its wholly owned subsidiary, QwikAgents, has engaged Caylent, a cloud services company and Amazon Web Services (AWS) Premier Tier Services Partner, to design and build an AWS-native QwikAgents platform.<\/p>\n<p>The collaboration represents the next phase in the evolution of the QwikAgents platform. Rather than migrating the existing application, Caylent will build a new AWS-native foundation that preserves QwikAgents&#8217; core functionality while enhancing scalability, performance and security for enterprise deployment and future product innovation. The engagement is also structured to align with AWS funding programs, with funding support expected from AWS and Caylent.<\/p>\n<p>\u201cThis collaboration is an important step in positioning QwikAgents for enterprise growth,\u201d said Eric Weisblum, Chief Executive Officer of Silo Pharma. \u201cBy combining our AI platform with Caylent&#8217;s AWS expertise, we&#8217;re creating a scalable foundation to accelerate commercialization and future innovation.\u201d<\/p>\n<p>The AWS-native platform is expected to enhance the scalability, performance and security of QwikAgents while accelerating future product development and supporting the platform&#8217;s long-term commercialization strategy.<\/p>\n<p>\n        <b>About Silo Pharma, Inc.<\/b>\n      <\/p>\n<p>\n        <b>QwikAgents<\/b>, Silo Pharma&#8217;s wholly owned artificial intelligence subsidiary, is a managed AI agent platform that delivers dedicated autonomous agents for research, content generation, scheduling, and workflow automation \u2014 each running in a persistent environment with proprietary smart-routing across multiple AI models. The subsidiary reflects Silo&#8217;s strategy to expand into high-growth technology markets while continuing to advance its core biopharmaceutical pipeline. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9K6NS4ihN_hVXTaR6lpDPDIj4TmCtZJRVcSGtMw7Ap4CHfXbmUGhbiYMycFQ61z2SxtHgjCaJ_zEx0tVitPYLq3BSAsKdnEKUUXygOnkexCL7JXSBF2mHY7SCuBl3SQxlKq7gR-wel1hMlWchCwgYU9HU9CuzSiAaqQcnadbksKMGm5ENoDbqppWOTvzz5tlDPiC-HpPCBd_v6E2MI6YW5qv_2GPR-ccFocmYJuXskQ=\" rel=\"nofollow\" target=\"_blank\">qwikagents.com<\/a><\/p>\n<p>\n        <b>Silo Pharma<\/b> is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company\u2019s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer\u2019s disease. Silo\u2019s research is conducted in collaboration with leading universities and laboratories.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SNm6qf9BFWv-jBQKKGlrtpSMZWwn-66SI4xErF1TQmGmcYT6HtnIzYfAUfsE50-2PLB2xAZfdHi1TvurO4MVV2NcrxAsAoHWtEUPiq6WEU-Q1U8cflSq3_ssxqgIQok1yfA0fkcg9_1wSaViRbpsm5CWKDH2HBI7k-DvtgA4cBnPJRZcsXMrOUj7aazp1I8yIEsieb0kP-gEajJSzVae8Z13AGPbHoPToIFoBy_xsqKzfKZ4a0cGIzZBQh21ZqiFFM2NHY6nAumu8lNMWR3ErtcO4g9HxBrI4aNpZfsKfnPUeRcvKnJ4hmRn9WQCn7LdnLf7xd_bm8pyKjEjE_LEz1MVIcRZsjkYsDbrOPlkH5G-jraO4NE92iEuo_QJOU5h76WNS6sqoEkQ0mKB2QzI4NCGVqoXygXQmIZTl-vSGZ46p7lrRB6pbgWJBqpTN2_mu3MH__6h0IidZR3lhGqsmj9JXasPdFY-_FPeIEfUPnJSG8EDvyASA3QFmTbu5KRBffjFDWzXfS158impgF3zO9yI-3hkLaxGyWpRVM70bX9sLrxypKOrlezTVugWlDklKQjAC53m8SHQjzlKG8c9D86IR-yyzA7gLN23adkSG_GyR9tsgw9f04qxsR0EqoV_MyNvuj3h61i3bq3EHFHllwBmc-Y5WuWtC_damJ9MYLwwFV4usw23VQkmgUFb0Rnpz3YKwB9kybLQE0m1xEhet-WvkuGTgVbxHO6dFYUiWKP0RyOuRjzoSOyuD_abB368S5VAx5Vo29XQGFAbVMDgXQLPdYfVmOeLjOpmVyAKbweP6n6tUKHngI6T6y65PyXQnOheJHLn9a98MwhBKbm4341GOZdOSYrzH-mBnTqO49BuoetwngXre0TTXUK3d_JDNCCny-IhateG4T4zkfodV_XZ7H6zba9dgkFoFJdQLrVsE4gyqW_fDZngUSANoQyAHr3Y8_9uAt7d2MnHXA9LfJZxpP-ho-d_jzj9oz5frk_DYCX6QWIIkcF_ZN501_ld\" rel=\"nofollow\" target=\"_blank\">silopharma.com<\/a><\/p>\n<p>\n        <br \/>\n        <b>Forward Looking Statements<\/b><br \/>\n        <br \/>This news release contains \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words \u201ccould\u201d, \u201cbelieve\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201ccontinue\u201d, \u201cpredict\u201d, \u201cpotential\u201d, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company\u2019s technology platforms, retaining and expanding the Company\u2019s customer base, fluctuations in consumer spending on the Company\u2019s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.<\/p>\n<p>\n        <b>Contact<\/b>\n      <\/p>\n<p>(800) 705-0120<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2Ve8mG5CfX9RYMAKJw9WGm433L6Pq5Wk8dGEEkKYQJV3QTrL1hzhCMgalMV68rxMfbX1AuyVrgp4OOGmIp7wllnKvZmShB05d631j6lBvZqqzFmyecq6mHeqRfjPrZ6t7qLr4wb9Qw5q6zfyYq5eflvmcJmWpeCAaeLjlh4p7p52DV1vJgqr6_up_Fpqib-3CiumnFBXVw2XTpY0-CTDj6j9cfMmtxQD6SmRd-DlkiDBjOh7lXfIThuOdNKujdUuidEL6tD_NoLF-RNMt_EQ_eEN9-M0cM4dlGYaaYj4v8l_1apHWCEs7SR8LNa5NtsdA-EHemLZENSzhg52tyi0OSdW2_RyVsPa3SdyV4npqZ-OYfFXWMWQ0x3GuJzywFX5mYf928gRWFJpEL4Sme-9SiGdBG_o3vnKGYXzUGGLMxSB_jaklcAu6CWbscxb6HHEUkL934seAdZM45HajlNPYdNBtCpRwC1yW5GrHGBHR75yHsBG_er5-y1icCdhDcPc0bVmkc6oZBRLoGd04pVrbQ==\" rel=\"nofollow\" target=\"_blank\">investors@silopharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDg1OCM3NzYxOTg2IzUwMDA2OTMzOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzczNDBhYmEtNjkzMy00ZGZmLTliMjUtOWY3ODU3NGJhYzA2LTUwMDA2OTMzOS0yMDI2LTA4LTA2LWVu\/tiny\/Silo-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption SARASOTA, FLA., Aug. 06, 2026 (GLOBE NEWSWIRE) &#8212; Silo Pharma (Nasdaq: SILO) (\u201cSilo\u201d or \u201cthe Company\u201d), a managed AI agent platform and developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that its wholly owned subsidiary, QwikAgents, has engaged Caylent, a cloud services company and Amazon Web Services (AWS) Premier Tier Services Partner, to design and build an AWS-native QwikAgents platform. The collaboration represents the next phase in the evolution of the QwikAgents platform. Rather than migrating the existing application, Caylent will build a new AWS-native foundation that preserves QwikAgents&#8217; core functionality while enhancing scalability, performance and security for enterprise &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-991400","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption SARASOTA, FLA., Aug. 06, 2026 (GLOBE NEWSWIRE) &#8212; Silo Pharma (Nasdaq: SILO) (\u201cSilo\u201d or \u201cthe Company\u201d), a managed AI agent platform and developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that its wholly owned subsidiary, QwikAgents, has engaged Caylent, a cloud services company and Amazon Web Services (AWS) Premier Tier Services Partner, to design and build an AWS-native QwikAgents platform. The collaboration represents the next phase in the evolution of the QwikAgents platform. Rather than migrating the existing application, Caylent will build a new AWS-native foundation that preserves QwikAgents&#8217; core functionality while enhancing scalability, performance and security for enterprise &hellip; Continue reading &quot;Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-06T17:33:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDg1OCM3NzYxOTg2IzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform\",\"datePublished\":\"2026-08-06T17:33:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\\\/\"},\"wordCount\":573,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDg1OCM3NzYxOTg2IzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\\\/\",\"name\":\"Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDg1OCM3NzYxOTg2IzUwMDA2OTMzOQ==\",\"datePublished\":\"2026-08-06T17:33:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDg1OCM3NzYxOTg2IzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDg1OCM3NzYxOTg2IzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform - Market Newsdesk","og_description":"Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption SARASOTA, FLA., Aug. 06, 2026 (GLOBE NEWSWIRE) &#8212; Silo Pharma (Nasdaq: SILO) (\u201cSilo\u201d or \u201cthe Company\u201d), a managed AI agent platform and developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that its wholly owned subsidiary, QwikAgents, has engaged Caylent, a cloud services company and Amazon Web Services (AWS) Premier Tier Services Partner, to design and build an AWS-native QwikAgents platform. The collaboration represents the next phase in the evolution of the QwikAgents platform. Rather than migrating the existing application, Caylent will build a new AWS-native foundation that preserves QwikAgents&#8217; core functionality while enhancing scalability, performance and security for enterprise &hellip; Continue reading \"Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-06T17:33:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDg1OCM3NzYxOTg2IzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform","datePublished":"2026-08-06T17:33:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/"},"wordCount":573,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDg1OCM3NzYxOTg2IzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/","name":"Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDg1OCM3NzYxOTg2IzUwMDA2OTMzOQ==","datePublished":"2026-08-06T17:33:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDg1OCM3NzYxOTg2IzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDg1OCM3NzYxOTg2IzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/991400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=991400"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/991400\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=991400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=991400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=991400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}